Theratechnologies Inc. is a Canadian biopharmaceutical company focused on discovering, developing and commercializing innovative therapies to address metabolic and endocrine disorders. Headquartered in Montréal, Quebec, the company leverages its expertise in peptide-based molecules to target conditions with significant unmet medical needs, including those associated with aging, HIV-related lipodystrophy and non-alcoholic fatty liver disease (NAFLD).
The company’s lead commercial product is Egrifta® (tesamorelin), a synthetic growth hormone-releasing factor analogue approved in the United States and Canada for reducing excess abdominal fat in HIV-infected patients with lipodystrophy. Egrifta marked the first regulatory approval of a therapy specifically indicated for this condition, and it continues to generate royalty and product sales through direct marketing in North America under Theratechnologies’ own commercialization infrastructure.
Beyond its marketed therapy, Theratechnologies maintains an active R&D pipeline aimed at expanding the use of tesamorelin into additional metabolic indications such as NAFLD, as well as pursuing novel peptide candidates in preclinical and early-stage clinical development. The company has entered licensing and collaboration agreements with partners in North America, Europe and Asia to facilitate late-stage trials and potential regulatory filings in new markets.
Founded in 1993, Theratechnologies is governed by a board of directors and led by a management team with deep experience in biotechnology, regulatory affairs and commercialization. The company operates primarily in Canada and the United States, while seeking strategic alliances to extend its geographic reach and accelerate the clinical advancement of its product candidates.
AI Generated. May Contain Errors.
